Small is still beautiful for biotech companies coming to market

Celltech's recent setback has not cured firms' enthusiasm for public listings, reports Sameena Ahmad

A rising tide of young biotechnology companies is planning to float on the UK stock market over the next few years - undeterred by Celltech's shock revelation last week that its leading drug for septic shock works no better than a sugar pill.

The crash in Celltech's shares will undoubtedly affect investor sentiment, which is vital for stock market debutants. Patrick Rousseau, CEO of Thallia, a French health food company hoping for a $100m (pounds 61m) float says: "I have heard of six IPOs [initial public offerings] due this summer now delaying until the autumn after Celltech."

But behind these delays, a huge queue of hopefuls is building up. Michael Ward, editor of biotechnology newsletter BioBusiness, estimates there are 700 European bioscience companies looking to raise public money over the next decade. Of the UK companies seeking to float in London, three - Powderject, Ethical Holdings and Galen - announced valuation details before Celltech's bombshell.

Waiting in the wings are Oxford Glycosciences, which recently appointed James Noble, former finance director of British Biotech, to its board, chemical designer Oxford Asymmetry, Cambridge-based Cenes, gene-therapy group Therexsys and cancer specialist, Antisoma.

Even more are eyeing up the UK from the Continent. Jeremy Curnock Cook, head of Rothschild's biotechnology investment fund, sees enormous growth in biotechnology in Europe. "These companies are 10 years behind the US in commercialising their research, but are now ready to raise serious money." France dominates this list which includes Biocom, a computer software group; IDM, a gene-therapy company; Cerep, a chemical screening specialist; gene-delivery company, Transgene, and drug delivery group, Biovector Therapeutics. Coming from Germany are Morphosys, which has developed a peptide antibody library and IDEA, which hopes to list on AIM. Brussels is offering IBT, Spain, PharmaMar, which makes drugs from marine plants and from Australia the agricultural genetic engineer, ForBio, is looking for a secondary listing this year. Pharming, the Dutch company which was planning a London summer listing, may now delay until the autumn, say sources.

Mr Ward of BioBusiness also notes a new trend for US-listed biotechs to seek a secondary quotation on the less crowded European markets. "Some of these US companies don't get much exposure at home where there are 300 plus biotechs. The UK has just 20 or so. Also many have subsidiaries on the Continent and so it is natural to seek more investors there." Sugen, which has a German base and is 20 per cent owned by Zeneca, plans to float in London late summer while US compatriot, Verigen, which has a Danish subsidiary, will list on AIM.

How many of these hopefuls will actually make it? Though Celltech was a sharp reminder of the volatility of biotechnology shares, most believe prospects for the right sort of newcomer remain good long term.

One reason is a growing understanding that failures are meant to happen in drug research. David Horrobin, chief executive of Scotia, one of the UK's largest listed biotechs, says: "Most small molecules fail. For every 10,000 evaluated, only one makes it to market." John Padfield, chief executive of Chiroscience, points out that biotechnology companies are particularly exposed to good and bad news: "Biotechs walk around naked - everything we say or do is scrutinised. Drugs die all the time within the big pharmaceutical companies, but investors never know about it."

The complexity of biotechnology companies is partly to blame for the collective panic in share prices after bad news from one company. Robert Alington Maguire of Baring Brothers says: "It is precisely because pharmaceutical companies are very complex and very different that people tend to judge them as the same." The small size of the UK biotech market is also critical. Dr Horrobin says: "There is still a lack of qualified analysts and journalists here. If people don't understand the technology it is easy for them to become wildly enthusiastic or overly negative."

However, that is changing. As Mr Curnock Cook notes: "A bigger market attracts more money, institutions have to take a position and more analysts start to follow the sector seriously." This results in a keener ability to differentiate companies on quality. Louis Nisbet, chief executive of Xenova, the recently floated UK group, says: "Institutions are becoming very clued up and are starting to recruit medically qualified fund managers." The realisation that biotechs are worth a serious look is also being driven by the growing number of alliances with big pharma groups eager to find innovative new products.

In addition, as Mark Brewer, analyst at Hoare Govett, points out, not all biotechs carry equal risk: "Not every company develops drugs from scratch. There is plenty in this sector for investors with a lower appetite for risk." Of the imminent floats, Galen is a mini-pharma company profitable for 30 years. Powderject doesn't make drugs at all but develops devices to deliver them. None has plans to scale back their flotation valuations post Celltech.

Nor should investors forget the potential for biotechs to rise from the dead. Cantab's shares, which crashed to little over 100p in 1995 after a lead drug failed, now trade at 917.5p. British Biotech, which lost its first cancer drug batimastat, is now capitalised at almost pounds 1.7bn. As Dr Horrobin points out: "Anyone who invested in biotechs at flotation have done much better than if they'd put the money in big drug company shares. We are all pretty successful investments."

PROMOTED VIDEO
News
Johnny Handle, Northumberland, Ted Relph, President of Lakeland Dialect Society, and Sid Calderbank, Lancashire, founder of the National Dialect Day
newsMeet the enthusiasts determined to stop them dying out
News
The data shows that the number of “unlawfully” large infant classes has doubled in the last 12 months alone
i100Mike Stuchbery, a teacher in Great Yarmouth, said he received abuse
Arts and Entertainment
The starship in Star Wars: The Force Awakens
filmsThe first glimpse of JJ Abrams' new film has been released online
Sport
Rio Ferdinand returns for QPR
sportRio Ferdinand returns from his three-game suspension today
News
The Speaker of the House will takes his turn as guest editor of the Today programme
arts + ents
News
ebooksNow available in paperback
Arts and Entertainment
St Peter’s Seminary in Cardross. Argyll, has remained derelict for more than 25 years
arts + ents
News
people

Watch the spoof Thanksgiving segment filmed for Live!
Sport
Billy Twelvetrees will start for England against Australia tomorrow with Owen Farrell dropping to the bench
rugbyEngland need a victory against Australia today
Arts and Entertainment
The cover of The Guest Cat – expect to see it everywhere
books
Sport
Tyson Fury poses outside the Imperial War Museum in south London ahead of his fight against Dereck Chisora
boxingAll British heavyweight clash gets underway on Saturday night
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Austen Lloyd: Company Secretary

Excellent Package: Austen Lloyd: EAST ANGLIA - SENIOR SOLICITOR LEVEL ROLE** -...

Citifocus Ltd: German Speaking Client Specialist

£Attractive Package: Citifocus Ltd: Prestigious asset management house seeks a...

Citifocus Ltd: Performance & Risk Oversight

£Negotiable: Citifocus Ltd: This is a varied role focusing on the firm's mutua...

h2 Recruit Ltd: Sales Director - SaaS (SME/Channel) - £140,000 OTE

£90000 - £140000 per annum + benefits: h2 Recruit Ltd: Are you a high achievin...

Day In a Page

Homeless Veterans Christmas Appeal: ‘We give them hope. They come to us when no one else can help’

Christmas Appeal

Meet the charity giving homeless veterans hope – and who they turn to when no one else can help
Should doctors and patients learn to plan humane, happier endings rather than trying to prolong life?

Is it always right to try to prolong life?

Most of us would prefer to die in our own beds, with our families beside us. But, as a GP, Margaret McCartney sees too many end their days in a medicalised battle
Thomas Cook's outgoing boss Harriet Green got by on four hours sleep a night - is that what it takes for women to get to the top?

What does it take for women to get to the top?

Thomas Cook's outgoing boss Harriet Green got by on four hours sleep a night and told women they had to do more if they wanted to get on
Christmas jumper craze: Inside the UK factory behind this year's multicultural must-have

Knitting pretty: British Christmas Jumpers

Simmy Richman visits Jack Masters, the company behind this year's multicultural must-have
French chefs have launched a campaign to end violence in kitchens - should British restaurants follow suit?

French chefs campaign against bullying

A group of top chefs signed a manifesto against violence in kitchens following the sacking of a chef at a Paris restaurant for scalding his kitchen assistant with a white-hot spoon
Radio 4 to broadcast 10-hour War and Peace on New Year's Day as Controller warns of cuts

Just what you need on a New Year hangover...

Radio 4 to broadcast 10-hour adaptation of War and Peace on first day of 2015
Cuba set to stage its first US musical in 50 years

Cuba to stage first US musical in 50 years

Claire Allfree finds out if the new production of Rent will hit the right note in Havana
Christmas 2014: 10 best educational toys

Learn and play: 10 best educational toys

Of course you want them to have fun, but even better if they can learn at the same time
Paul Scholes column: I like Brendan Rodgers as a manager but Liverpool seem to be going backwards not forwards this season

Paul Scholes column

I like Brendan Rodgers as a manager but Liverpool seem to be going backwards not forwards this season
Lewis Moody column: Stuart Lancaster has made all the right calls – now England must deliver

Lewis Moody: Lancaster has made all the right calls – now England must deliver

So what must the red-rose do differently? They have to take the points on offer 
Cameron, Miliband and Clegg join forces for Homeless Veterans campaign

Cameron, Miliband and Clegg join forces for Homeless Veterans campaign

It's in all our interests to look after servicemen and women who fall on hard times, say party leaders
Millionaire Sol Campbell wades into wealthy backlash against Labour's mansion tax

Sol Campbell cries foul at Labour's mansion tax

The former England defender joins Myleene Klass, Griff Rhys Jones and Melvyn Bragg in criticising proposals
Nicolas Sarkozy returns: The ex-President is preparing to fight for the leadership of France's main opposition party – but will he win big enough?

Sarkozy returns

The ex-President is preparing to fight for the leadership of France's main opposition party – but will he win big enough?
Is the criticism of Ed Miliband a coded form of anti-Semitism?

Is the criticism of Miliband anti-Semitic?

Attacks on the Labour leader have coalesced around a sense that he is different, weird, a man apart. But is the criticism more sinister?
Ouija boards are the must-have gift this Christmas, fuelled by a schlock horror film

Ouija boards are the must-have festive gift

Simon Usborne explores the appeal - and mysteries - of a century-old parlour game